Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients

Y. Wang, T. K. Choueiri, J. L. Lee, M. H. Tan, S. Y. Rha, S. A. North, C. K. Kollmannsberger, D. F. McDermott, D. Y.C. Heng

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.

Original languageEnglish
Pages (from-to)1433-1437
Number of pages5
JournalBritish journal of cancer
Volume110
Issue number6
DOIs
Publication statusPublished - 2014 Mar 18

Bibliographical note

Funding Information:
TKC has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. CK has an advisory role at Pfizer, Novartis, and GlaxoSmithKline and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. J-LL has received honoraria from Bayer, Pfizer, GSK, Janssen and research funding from Bayer. DYCH has an advisory role at Aveo, Pfizer, Novartis, and Bayer. YW, SAN, M-HT, S-YR, and DFM declare that they have no conflicts of interest.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients'. Together they form a unique fingerprint.

Cite this